Back to top

NewAmsterdam Pharma initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of NewAmsterdam Pharma (NAMS) with an Outperform rating and $58 price target The firm’s cited a few reasons for its ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NewAmsterdam Pharma Company N.V. (NAMS)